Lombard Odier Asset Management (USA)’s Heron Therapeutics HRTX Stock Holding History

Lombard Odier Asset Management (USA)’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-175,000	Closed	-$2.42M	–	230
2017 Q2	$2.42M	Hold	175,000	–	–	0.19%	126
2017 Q1	$2.63M	Buy	175,000 +75,000	+75%	+$1.04M	0.25%	111
2016 Q4	$1.31M	Sell	100,000 -75,000	-43%	-$1.18M	0.17%	123
2016 Q3	$3.02M	Buy	+175,000	New	+$3.25M	0.28%	110
2016 Q1	–	Sell	-91,938	Closed	-$2.46M	–	169
2015 Q4	$2.46M	Sell	91,938 -25,562	-22%	-$684K	0.24%	114
2015 Q3	$2.87M	Sell	117,500 -72,500	-38%	-$2.42M	0.25%	119
2015 Q2	$5.92M	Buy	+190,000	New	+$3.57M	0.42%	78

Other funds holding HRTX

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return

Lombard Odier Asset Management (USA)'s HRTX Position: Q3 2017 in Review

Lombard Odier Asset Management (USA) sold out of Heron Therapeutics (HRTX) in Q3 2017, closing a stake of 175,000 shares — an estimated $2.42M sold.

Lombard Odier Asset Management (USA) first reported a position in HRTX in Q2 2015 and held it in 7 quarters. The position peaked at $5.92M in Q2 2015. 104 funds tracked by Wall St. Rank hold HRTX as of Q3 2017.

Lombard Odier Asset Management (USA) reported no remaining Heron Therapeutics position as of Q3 2017 after selling out during the quarter.
Lombard Odier Asset Management (USA) sold 175,000 Heron Therapeutics shares in Q3 2017, an estimated $2.42M.
Lombard Odier Asset Management (USA) first reported a position in Heron Therapeutics in Q2 2015 and held it in 7 quarters.
Lombard Odier Asset Management (USA)'s Heron Therapeutics position peaked at $5.92M in Q2 2015.
104 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2017.

Based on Lombard Odier Asset Management (USA)'s 13F filing for Q3 2017, filed 14 Nov 2017.